A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer Meeting Abstract
| Authors: | Elit, L.; Konner, J. A.; Armstrong, D. K.; Buck, M.; Dean, A.; Finkler, N. J.; Hulstine, A.; Schweizer, C.; Phillips, M.; Weil, S. |
| Abstract Title: | A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer |
| Meeting Title: | 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 28 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2010 Jun 4-8 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2010-05-20 |
| Start Page: | 45s |
| Language: | English |
| ACCESSION: | WOS:000208852002255 |
| DOI: | 10.1200/jco.2010.28.15_suppl.tps255 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS255 -- Source: Wos |
